- Home
- JXG vs AIMD Comparison
JXG vs AIMD Comparison
Compare JXG & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | AIMD |
|---|---|---|
| Founded | N/A | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 10.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JXG | AIMD |
|---|---|---|
| Price | $4.20 | $1.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 35.4K | 18.4K |
| Earning Date | 11-05-2025 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $46,835,624.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | 21.68 | ★ 178.19 |
| 52 Week Low | $3.01 | $1.61 |
| 52 Week High | $49.95 | $4.75 |
Technical Indicators
Market Signals| Indicator | JXG | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 43.68 |
| Support Level | $4.01 | $1.82 |
| Resistance Level | $4.74 | $1.98 |
| Average True Range (ATR) | 0.68 | 0.10 |
| MACD | -0.28 | 0.03 |
| Stochastic Oscillator | 23.53 | 71.69 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.